APOL1 Genotyping CTA Clinical Performance Study
NCT06839833
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Clinical Performance Study SP2024001, is a prospective, interventional study to assess the clinical performance of the APOL1 Genotyping Clinical Trial Assay (CTA) in the intended use population and environment.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- APOL1-mediated Kidney Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Almac Diagnostic Services LLC
- Last updated on ClinicalTrials.gov
- July 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
North Carolina · 1
- Almac Diagnostic Services LLC · Durham, NC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.